Blood-Derived clots could protect jaw bone after tooth removal

NCT ID NCT07673848

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study investigates whether a patient's own platelet concentrate, called A-PRF, can improve early wound healing after tooth extraction in people at high risk for medication-related osteonecrosis of the jaw (MRONJ). Participants are adults who have taken or are taking bone-strengthening or cancer medications that increase MRONJ risk. The trial uses advanced imaging and protein analysis to track healing over 15 days, with a final check at 180 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

autogenous platelet concentrates (A-PRF)

What this could lead to

If effective, this approach could reduce the risk of jaw bone death after dental extractions in patients taking bone-strengthening or cancer medications.

What could go wrong

This is a small, early-stage study with 44 participants, so results may not apply to all patients. The procedure involves blood draws and centrifugation, and benefits over standard care are not yet proven.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEDICATION-RELATED OSTEONECROSIS OF THE JAW are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteonecrosis of the jaw

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.